AbbVie presented new SKYRIZI data: what it means for AbbVie stock

Published on 10/15/2026 at 11:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AFFIRM remission reached 35.80 percent versus 9.10 percent placebo at week 24. AbbVie stock costs EUR 254.70 on October 15, 2026, 0.31 percent above Xetra close.

Pipeline and calendar

AFFIRM endoscopic remission reached 35.80 percent versus 9.10 percent with placebo at week 24 on October 13, 2026.
AbbVie reported USD 16.99 billion in second-quarter 2026 revenue, up 10.20 percent year over year.
AbbVie stock trades at EUR 254.70 at 11:19 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.31 percent above the Xetra close of October 14, 2026.
AbbVie will report third-quarter 2026 results on October 30, 2026, before the market opens.

Schwarz-Weiß-Reportagefoto einer Wissenschaftlerin am Mikroskop mit dramatischem Seitenlicht — AbbVie Inc. US00287Y1091 Schwarz Weiß Reportage Wissenschaftlerin konzentriert am Mikroskop im sterilen Labor, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 254.70 at Lang & Schwarz on October 15, 2026, at 11:19 a.m. CEST, 0.31 percent above the Xetra close of October 14, 2026 at EUR 253.90. The company presented new Phase 3 AFFIRM results for subcutaneous SKYRIZI in Crohn's disease on October 13, 2026, according to StockTitan. The data give investors a measurable update on one of AbbVie's main growth franchises before the company's next earnings report.

SKYRIZI data add clinical depth

At week 24, endoscopic remission reached 35.80 percent with SKYRIZI versus 9.10 percent with placebo. Ulcer-free endoscopy reached 36.60 percent versus 9.10 percent. The results covered induction responders who entered maintenance, while the subcutaneous induction regimen remained under review by the U.S. Food and Drug Administration and the European Medicines Agency, according to StockTitan.

What do the results mean for growth?

The commercial backdrop was already quantified in AbbVie's second-quarter 2026 report. Total revenue reached USD 16.99 billion, up 10.20 percent from the prior-year quarter, while adjusted earnings per share were USD 3.65. SKYRIZI sales reached USD 5.50 billion, up 24.00 percent operationally, according to the Yahoo Finance transcript of the July 31, 2026 earnings call. The new study results therefore add a pipeline and regulatory milestone to an already growing product base.

Three dated steps for AbbVie

On July 31, 2026, AbbVie reported second-quarter revenue of USD 16.99 billion and adjusted earnings per share of USD 3.65. On October 1, 2026, the company announced that third-quarter results would be released on October 30, 2026. On October 13, 2026, the AFFIRM update reported 35.80 percent endoscopic remission at week 24 versus 9.10 percent for placebo.

Dates investors can measure

AbbVie's next two dated milestones are the October 15, 2026 ex-dividend date and the October 30, 2026 third-quarter results release. The October 30 announcement is scheduled before the U.S. market opens, according to StockTitan. The dividend record date is October 15, 2026, with a quarterly payment of USD 1.73 per share scheduled for November 16, 2026, according to MarketBeat.

Stock holds above the Xetra close

The euro quotation was EUR 254.70 at Lang & Schwarz on October 15, 2026, at 11:19 a.m. CEST, 0.31 percent above the Xetra close of October 14, 2026 at EUR 253.90. On the NYSE, AbbVie was last quoted at USD 283.52 on October 14, 2026, while its 52-week range was USD 190.75 to USD 285.40.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.